Johnson & Johnson v. Samsung Bioepis Co Ltd
Third Circuit: Biosimilar Renflexis Does Not Infringe Remicade Patents
ca3 · 2026-04-14 · Defendant Win · Impact: 75/100
Johnson & Johnson v. Samsung Bioepis Co Ltd, decided by Third Circuit on April 14, 2026, resulted in a defendant win outcome. The Third Circuit affirmed the District Court's grant of summary judgment ...